These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38436114)

  • 41. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
    Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
    J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study.
    Zhou S; Lai J; Wu C; Liu Y; Liu Y; Zhao J; Xu D; Tian X; Li M; Zhao Y; Wang Y; Wang Q; Zeng X
    Front Immunol; 2022; 13():928861. PubMed ID: 35983058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
    Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
    Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.
    Ono N; Kai K; Maruyama A; Sakai M; Sadanaga Y; Koarada S; Inoue T; Tada Y
    Rheumatology (Oxford); 2019 May; 58(5):786-791. PubMed ID: 30541137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN-α.
    Wang K; Zhao J; Wu W; Xu W; Sun S; Chen Z; Fu Y; Guo L; Du H; Ye S
    Front Immunol; 2021; 12():743704. PubMed ID: 34721411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody.
    Shanshan L; Yamei Z; Ling Z; Xin L; Guochun W
    Clin Rheumatol; 2022 Mar; 41(3):757-763. PubMed ID: 34718893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age.
    Yamaguchi K; Yamaguchi A; Onuki Y; Itai M; Kashiwagi C; Takehara K; Aoki S; Kanaya A; Taguchi K; Umetsu K; Oshima K; Uchida M; Kimura H; Kasahara M; Takemura M; Hara K; Sekiguchi A; Motegi SI; Muro Y; Nakasatomi M; Motohashi R; Sakairi T; Nakagawa J; Hiromura K; Obokata M; Kurabayashi M; Maeno T
    Mod Rheumatol; 2021 Jan; 31(1):177-185. PubMed ID: 32149542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
    Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
    Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population.
    Lin JM; Zhang YB; Peng QL; Yang HB; Shi JL; Gu ML; Zhao WM; Wang GC
    HLA; 2017 Dec; 90(6):354-359. PubMed ID: 29106035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.
    Lu X; Peng Q; Wang G
    Nat Rev Rheumatol; 2024 Jan; 20(1):48-62. PubMed ID: 38057474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K
    Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications.
    Ye Y; Chen Z; Jiang S; Jia F; Li T; Lu X; Xue J; Lian X; Ma J; Hao P; Lu L; Ye S; Shen N; Bao C; Fu Q; Zhang X
    Nat Commun; 2022 Oct; 13(1):6458. PubMed ID: 36309526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.